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if the corresponding objective was not met (Table 1). 
Radiotherapy plan data was submitted by treatment centres 
in DICOM or RTOG format and 52 randomly selected plans 
were processed with the Computational Environment for 
Radiotherapy Research (CERR) software [2] which enabled i) 
outlining of target and organ-at-risk structures and ii) dose 
distribution and dose volume histograms to be assessed.  
 
 
Table 1: Summary of quantities assessed during review of 
radiotherapy plans.  
 
Results: The total number of deviations identified was ~11% 
of the total possible. 81% of plans had two or fewer 
deviations indicating good adherence to the trial protocol 
(Figure 1).  64% of deviations were related to the rectum. 
There were 5 dose volume objectives associated with the 
rectum and it was recognised that failure to meet one rectal 
constraint generally corresponded with further deviations.  
All patient plans used 3 or 4 gantry angles in a 'pelvic-brick' 
beam distribution with or without the posterior beam. No 
patient failed the ICRU Max D1.8cc constraint. 
 
Figure 1: Histogram showing number of deviations recorded 
per plan reviewed. The type of deviation recorded is 
indicated by the colour of the bars. 
Conclusions: Deviation from the clinical trial protocol has 
the potential to confound the study question and quality 
assurance is therefore essential when comparing different 
treatments. Our analysis of a subset of the radiotherapy plans 
demonstrates good understanding and adherence to the 
ProtecT protocol.  
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Purpose/Objective: Quality assurance (QA) of volumetric-
modulated radiotherapy (VMAT) has developed substantially 
in recent years. One of the most important roles of 
dosimetric verification is to detect errors in plan 
implementation on the treatment machine. Such errors 
include incorrect mechanical settings, differences in doses, 
and shifts in the multileaf collimators. To verify that the 
treatment plan is correct, it is necessary to use proper 
measuring tools (e.g., 2D and 3D detector arrays) in addition 
to an analytical method (e.g., gamma method) that includes 
tolerance and passing criteria that are sufficiently sensitive 
to achieve reliable results. The detector arrays, however, are 
limited by their resolution. Understanding the limitations of 
these devices is therefore crucial. The aim of the work was 
to characterize the sensitivity to induced errors of 2D-arrays 
for FFF prostate plan verification. 
Materials and Methods: The new 2D ion chamber array 1500 
and the well-known arrays, seven29 and SRS1000 with 
rotational phantom cylindrical Octavius® 4D and Verisoft 6.0 
software (PTW, Freiburg, Germany) were used to determine 
the sensitivity to induced errors. Measured and calculated 
dose distributions of VMAT high-fractionated FFF prostate 
plans were compared using the 3D gamma analysis by global 
(maximum) and local dose methods with a 5% threshold for 
various tolerance parameters DTA [mm] and DD [%] were 1.0; 
1.5; 2.0; 2.5; 3.0; 3.5. The sensitivity of the 2D-arrays was 
tested using the errors inserted into VMAT plan: a collimator 
rotation angle (1; 2; 3 degree), dose (difference in %: 0.5; 
1.0; 2.0) and MU errors (5MU was missing in each field at the 
end of gantry position). Later, the erroneous plans were 
compared to measure error-free dose distributions on arrays 
on a linear accelerator (TrueBeam, Varian). 
Results: The results for each of the arrays analyzed differed 
and were strictly dependent on the resolution of the 
detector. The results obtained were as follow: for gamma 
criteria 2/2 (DTA[mm]/DD[%]): SRS1000 (L99.5; G99.9), 1500 
(L95.8; G99.0), 729 (L92.2; G97.0); for 3/3: SRS1000 (L99.0; 
G100.0), 1500 (L99.4; G100.0), 729 (L98.9; G99.7). The 
highest differences were observed for inserted errors: coll 3º, 
dose lowered by 2.0% and MU errors (L2/2; 1500): 94.0; 89.0; 
95.0, respectively. The sensitivity of arrays to errors was 
presented in Fig.1. 
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Conclusions: The commonly used gamma index criteria of 
DD3%/DTA 3 mm distance to agreement may potentially mask 
clinically-relevant errors. Dose differences calculated from 
the maximum of prescribed doses to high fraction doses were 
less evident than for the local dose-differences method. For 
geometric errors the most precise results were obtained for 
high resolution SRS1000 array. All of the researched arrays 
proved good response for dose induced errors. Therefore, 
each detector and technique should be set to the proper 
gamma tolerance parameters to identify possible deviations 
from the treatment plan. 
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Purpose/Objective: To assess, by means of treatment plan 
comparison along with normal tissue complication probability 
(NTCP) modelling, the feasibility of subpopulation grouping 
according to tumour location in head and neck cancer (HNC) 
patients regarding identification of patients with highest 
benefit from intensity-modulated proton therapy (IMPT) 
compared to intensity-modulated photon therapy (IMRT). 
Furthermore, to assess the feasibility for both IMRT and IMPT 
of two different dose escalation (DE) levels with respect to 
NTCP. 
Materials and Methods: For 45 HNC patients IMRT was 
compared to IMPT with two different DE levels implemented 
via the simultaneous integrated boost technique. A treatment 
schedule was defined allowing for a patient stratification by 
functional imaging after 20 Gy of treatment according to risk 
of recurrence. Changes in patient anatomy during the course 
of treatment were considered using a one-time adaptation 
strategy. Evaluation of physical dose distributions and of the 
resulting NTCP values were performed using modern models 
for acute mucositis, xerostomia, aspiration, dysphagia, 
laryngeal oedema and trismus. Three patient subgroups were 
defined based on the primary tumour location: (A) in the 
upper head and neck area, (B) in the lower head and neck 
area, and (C) extending in both areas. 
Results: In general, IMPT reduced the NTCP values in 
comparison to IMRT while keeping similar target coverage for 
all patients. The level of reduction varied between different 
NTCP models (e.g. small: <1% for impact of swallowing liquid 
food, modest: 5% for mucositis, and large: >10% for physician 
rated dysphagia). Physical dose parameters were also 
reduced in most cases except for skin doses. Subgroup 
analyses showed a higher reduction of swallowing related 
side effects by IMPT for patients with tumours in the upper 
head and neck area (group A), while the risk of acute 
mucositis was reduced in patients with tumours in the larynx 
region (group B). For other toxicities based on NTCP 
evaluation, no subgroup-specific benefit by IMPT could be 
identified. Regardless of subgroups, the DE level had only 
little impact on most toxicity risks except for the aspiration 
model based on the pharyngeal constrictor muscles (PCM). 
Figure 1 illustrates changes in NTCP for the two treatment 
techniques (NTCPIMRT-NTCPIMPT: a-c) and for the two DE levels 
(NTCP2.6Gy-NTCP2.3Gy: d). 
Conclusions: IMPT reduced all NTCP values compared to 
IMRT. Subgrouping can help to identify patients who may 
benefit most from the use of IMPT. Thus, it can be a useful 
tool in the clinic where there are limited treatment 
resources. The individual benefit within the subgroups may 
differ and should be evaluated by individual treatment plan 
comparisons for selected patients. The used DE levels are 
both feasible as they did not impact the calculated NTCP 
values except for one. These results need to be confirmed in 
prospective clinical trials. 
